Jump to content

Celebrex (celecoxib) did not extend progression free survival in metastatic or high-risk


Recommended Posts

Celecoxib shows no evidence of activity when it’s added to hormone therapy in men with metastatic or high-risk nonmetastatic prostate cancer, according to first results from the six-arm STAMPEDE trial.

The use of celecoxib plus hormone therapy did not extend failure-free survival, compared with hormone therapy alone (adjusted hazard ratio, 0.98). The 305 failure-free survival events were largely prostate-specific antigen (PSA) failures in 78% of both groups and new metastases in 16% of both groups, Dr. Noel W. Clarke reported on behalf of the STAMPEDE investigators at the European Multidisciplinary Cancer Congress.

Other failure-free survival events were local progression in 2% of both groups, lymph node invasion in 2% of the hormone-only group and in 0% of the hormone-plus-celecoxib group, and prostate cancer-related death in 1% and 4%, respectively.

Toxicity among the 874 patients was not significantly different, with 23% of the hormone-only group and 25% of the celecoxib group experiencing any grade 3-5 toxicity, he said.

Note that the trial used PSA progression.

Fuller account here:


To see this article on another site you may have to subscribe to that site. Subscribing is often free.

Link to comment
Share on other sites


So Celebrex by itself does not look promising in human body trials.

Wonder if combo with statins does?

Regards Tony

Link to comment
Share on other sites


Could be.

There is an enormous amount of work to be done on combinations.

Just this past week I heard a talk by the Canadian researcher Dr Vasundara Venkateswaran about how the anti-prostate cancer effect of Metformin (a diabetes drug widely used, especially in early Type II) is enhanced in the presence of lycopene (present in cooked tomatoes).

She also pointed out that although the SELECT trial had found out that Vitamin E and Selenium did not prevent prostate cancer (and that Vitamin E may do harm), her work showed that while the combination was not effective by itself, adding a third to the mix (lyocpene) made the triple combo effective.

This may explain the varying results of trials of lycopene (or tomato consumption) against prostate cancer.

Her work was in mice infected with human prostate cancer tumors.

Message to take away:

We are built to run on a complex diet with many constituents.

Making some things work often depends on several factors being present at once.

Until science teases out the relationships, we can only depend upon a balanced diet, and perhaps a little intuition.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...